CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing O304, a small molecule that activates AMP-activated protein kinase (AMPK) to treat type 2 diabetes and its complications. The aim is to validate its effectiveness in clinical trials and ultimately provide a new treatment option for patients.
This project aims to close the gap to the market for a small molecule AMP activated protein kinase (AMPK) activator,denoted O304, as a novel first-in-class drug for the treatment of type 2 diabetes (T2D) and associated cardiovascularcomplications, including heart failure and peripheral arterial disease.The number of adults around the world with diabetes quadrupled from 108 million in 1980 to 422 million in 2014.
About 90%of these people have type 2 diabetes — a major cause of kidney failure, bli…
BETAGENON AB
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
